US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
US5747469A
(en)
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
CA2108144A1
(en)
|
1991-03-06 |
1992-09-07 |
Jack A. Roth |
Methods and compositions for the selective inhibition of gene expression
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
DE69535178T2
(de)
*
|
1994-06-10 |
2006-12-14 |
Genvec, Inc. |
Adenoviren-vektor systeme und zelllinien
|
FR2722507B1
(fr)
*
|
1994-07-12 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Adenovirus comportant un gene codant pour une no synthase
|
FR2724320B1
(fr)
*
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
FR2725213B1
(fr)
*
|
1994-10-04 |
1996-11-08 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation en therapie genique
|
FR2726285B1
(fr)
*
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
CN1136920C
(zh)
|
1995-02-28 |
2004-02-04 |
加利福尼亚大学董事会 |
基因转移介导的血管形成疗法
|
FR2731710B1
(fr)
*
|
1995-03-14 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US5698202A
(en)
*
|
1995-06-05 |
1997-12-16 |
The Wistar Institute Of Anatomy & Biology |
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
|
US6019978A
(en)
|
1995-06-05 |
2000-02-01 |
The Wistar Institute Of Anatomy And Biology |
Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
JP4051416B2
(ja)
*
|
1995-06-15 |
2008-02-27 |
クルーセル ホランド ベスローテン フェンノートシャップ |
遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
AUPN477695A0
(en)
*
|
1995-08-14 |
1995-09-07 |
Commonwealth Scientific And Industrial Research Organisation |
Gene therapy
|
FR2740344B1
(fr)
*
|
1995-10-31 |
1997-11-21 |
Rhone Poulenc Rorer Sa |
Application de la proteine gax au traitement de cancers
|
JP2002512501A
(ja)
*
|
1996-07-03 |
2002-04-23 |
メリアル インコーポレイテッド |
外来性dnaを含む組換えイヌアデノウィルス(cav)
|
AU4255397A
(en)
*
|
1996-09-06 |
1998-03-26 |
Trustees Of The University Of Pennsylvania, The |
Chimpanzee adenovirus vectors
|
CA2288306A1
(en)
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
JP2002516061A
(ja)
|
1997-10-14 |
2002-06-04 |
ダーウィン モレキュラー コーポレイション |
チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
US6653088B1
(en)
|
1997-10-24 |
2003-11-25 |
Aventis Pharma S.A. |
Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
|
JP2002500039A
(ja)
|
1998-01-08 |
2002-01-08 |
アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド |
機能あるヒトリポタンパク質(a)を発現するトランスジェニックウサギ
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
EP1105479B1
(en)
|
1998-08-11 |
2011-01-12 |
Darwin Discovery Limited |
Identification of the gene causing the mouse scurfy phenotype and its human ortholog
|
NZ552959A
(en)
|
1998-11-27 |
2008-06-30 |
Darwin Discovery Ltd |
Compositions and methods for increasing bone mineralization
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
US7063850B1
(en)
|
1998-12-22 |
2006-06-20 |
University Of Tennessee Research Foundation |
Protective antigen of group A Streptococci
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
FR2794771B1
(fr)
*
|
1999-06-11 |
2001-08-10 |
Aventis Pharma Sa |
Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
|
FR2799472B1
(fr)
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
AU2460001A
(en)
*
|
1999-12-27 |
2001-07-09 |
Regents Of The University Of California, The |
Gene therapy for congestive heart failure
|
ATE466882T1
(de)
|
2000-01-12 |
2010-05-15 |
Univ Yale |
Nogo rezeptor-vermittelte blockade des axonalen wachstums
|
KR100872884B1
(ko)
|
2000-03-24 |
2008-12-10 |
바이오스피어 메디칼 인코포레이티드 |
능동 색전화용 미소구
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
DK1355918T5
(da)
|
2000-12-28 |
2012-02-20 |
Wyeth Llc |
Rekombinant beskyttelsesprotein af streptococcus pneumoniae
|
DE60228477D1
(de)
|
2001-05-08 |
2008-10-02 |
Darwin Molecular Corp |
Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
|
AUPR518501A0
(en)
|
2001-05-22 |
2001-06-14 |
Unisearch Limited |
Yin yang-1
|
AU2002325346A1
(en)
|
2001-07-05 |
2003-01-21 |
Aventis Pharma S.A. |
Method of administration of a gene of interest to the heart and vasculature
|
US7582425B2
(en)
|
2001-09-21 |
2009-09-01 |
The Regents Of The University Of Michigan |
Atlastin
|
US7108975B2
(en)
|
2001-09-21 |
2006-09-19 |
Regents Of The University Of Michigan |
Atlastin
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
AU2002365184A1
(en)
|
2001-10-26 |
2003-07-30 |
Id Biomedical Corporation Of Washington |
Efficient protein expression system
|
CA2469623C
(en)
|
2001-12-12 |
2012-05-29 |
F H Faulding & Co Limited |
Composition for the preservation of viruses
|
US20030158112A1
(en)
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
JP4563171B2
(ja)
|
2002-05-24 |
2010-10-13 |
シェーリング コーポレイション |
中和ヒト抗igfr抗体
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
FR2845395B1
(fr)
*
|
2002-10-08 |
2008-05-30 |
Agronomique Inst Nat Rech |
Vecteurs adenoviraux recombinants et leurs applications
|
US9532994B2
(en)
|
2003-08-29 |
2017-01-03 |
The Regents Of The University Of California |
Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
NZ551443A
(en)
|
2004-05-26 |
2010-01-29 |
Schering Ag |
Chimeric adenoviruses for use in cancer treatment
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
JP4772045B2
(ja)
|
2004-07-16 |
2011-09-14 |
アメリカ合衆国 |
Cmv/r核酸コンストラクトを含むaidsに対するワクチン
|
KR20130114758A
(ko)
|
2005-05-27 |
2013-10-17 |
오스페달레 산 라파엘 에스.알.엘. |
Mi-rna를 포함하는 유전자 벡터
|
US9670244B2
(en)
|
2006-02-27 |
2017-06-06 |
The Regents Of The University Of California |
Oxysterol compounds and the hedgehog pathway
|
CN101495633B
(zh)
|
2006-07-28 |
2015-01-07 |
塞诺菲-安万特股份有限公司 |
用于治疗肿瘤的组合物和方法
|
JP5238710B2
(ja)
|
2006-10-19 |
2013-07-17 |
シーエスエル、リミテッド |
インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト
|
EP2530090A3
(en)
|
2006-10-19 |
2013-01-23 |
CSL Limited |
Anti-IL-13R alpha 1 antibodies and their uses thereof
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2231164A1
(en)
|
2007-12-03 |
2010-09-29 |
The Regents of the University of California |
Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
|
NZ614064A
(en)
|
2008-11-05 |
2015-04-24 |
Wyeth Llc |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
|
WO2010065613A2
(en)
|
2008-12-03 |
2010-06-10 |
The Johns Hopkins University |
Annexina2 as immunological target
|
RU2620970C2
(ru)
*
|
2008-12-04 |
2017-05-30 |
КьюРНА,Инк., |
Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
AU2011227050B2
(en)
|
2010-03-19 |
2016-12-08 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
EP3299464B1
(en)
*
|
2010-05-26 |
2019-10-02 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
CN109112126B
(zh)
*
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
HRP20210242T4
(hr)
|
2010-08-23 |
2024-05-10 |
Wyeth Llc |
Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
|
CN103096920B
(zh)
|
2010-09-10 |
2016-03-23 |
惠氏有限责任公司 |
脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
|
US9458456B2
(en)
|
2011-04-01 |
2016-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
WO2013103401A1
(en)
|
2012-01-06 |
2013-07-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
BR122016004924A2
(pt)
|
2012-03-09 |
2019-07-30 |
Pfizer Inc. |
Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
|
JP6262723B2
(ja)
|
2012-05-07 |
2018-01-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
オキシステロールアナログoxy133は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US9222142B2
(en)
*
|
2013-01-15 |
2015-12-29 |
The Regents Of The University Of California |
Adenoviruses and their use
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
CA2911205A1
(en)
|
2013-05-02 |
2014-11-06 |
The Regents Of The University Of California |
Bone-selective osteogenic oxysterol-bone targeting agents
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
LT3021859T
(lt)
|
2013-10-25 |
2018-06-11 |
Psioxus Therapeutics Limited |
Onkolitiniai adenovirusai su heterologiniais genais
|
EP3107939B1
(en)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
SG10201912858VA
(en)
|
2014-06-17 |
2020-02-27 |
Nippon Shinyaku Co Ltd |
Antisense nucleic acids
|
US20180008727A1
(en)
|
2015-01-30 |
2018-01-11 |
The Regents Of The University Of California |
Spinal subpial gene delivery system
|
AU2016221318B2
(en)
|
2015-02-19 |
2020-06-25 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EP3391892A1
(en)
|
2015-04-30 |
2018-10-24 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding a b7 protein
|
CN108289909A
(zh)
|
2015-10-19 |
2018-07-17 |
巴尔的摩马里兰大学 |
用于产生工程改造的人原代血液树突细胞系的方法
|
JP7064437B2
(ja)
|
2015-12-17 |
2022-05-10 |
サイオクサス セラピューティクス リミテッド |
抗tcr複合体抗体又は断片をコードするb群アデノウイルス
|
KR102489437B1
(ko)
|
2016-03-28 |
2023-01-16 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
뉴런 과흥분성 치료를 위한 방법 및 조성물
|
US11560412B2
(en)
|
2016-04-01 |
2023-01-24 |
University Of Maryland, Baltimore |
Compositions comprising GRIM-19 therapeutics and methods of use
|
CN116179580A
(zh)
|
2016-04-20 |
2023-05-30 |
能源环境和技术研究中心O.A., M.P. |
用于增强pklr的基因表达的组合物和方法
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
NZ751014A
(en)
|
2016-09-20 |
2023-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
New ehv insertion site orf70
|
CA3036386A1
(en)
|
2016-09-20 |
2018-03-29 |
Boehringer Ingelheim Vetmedica Gmbh |
Canine adenovirus vectors
|
AR109538A1
(es)
|
2016-09-20 |
2018-12-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Vacuna contra la gripe porcina
|
EP3516064A1
(en)
|
2016-09-20 |
2019-07-31 |
Boehringer Ingelheim Vetmedica GmbH |
New promoters
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症(als)の治療
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
US11642422B2
(en)
|
2017-10-16 |
2023-05-09 |
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A, M.P. |
Lentiviral vectors for delivery of PKLR to treat pyruvate kinase deficiency
|
US20210361318A1
(en)
|
2018-07-02 |
2021-11-25 |
Voyager Therapeutics, Inc. |
Cannula system and use thereof
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
EP4192487A1
(en)
|
2020-08-07 |
2023-06-14 |
Spacecraft Seven, LLC |
Plakophilin-2 (pkp2) gene therapy using aav vector
|
JP2024516400A
(ja)
|
2021-04-30 |
2024-04-15 |
カリヴィル イムノセラピューティクス, インコーポレイテッド |
修飾されたmhc発現のための腫瘍溶解性ウイルス
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|